Wang, X. et al. 2020. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis: Abiraterone versus enzalutamide in mCRPC. Journal of Pharmacy & Pharmaceutical Sciences. 23, (Nov. 2020), 451–461. DOI:https://doi.org/10.18433/jpps31003.